Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Conditions:   Cutaneous Melanoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Urothelial Carcinoma;   Renal Cell Carcinoma
Interventions:   Biological: GEN-009 Adjuvanted Vaccine;   Drug: Nivolumab
Sponsor:   Genocea Biosciences, Inc.
Recruiting

https://ift.tt/2vMstA8